Member Info for Early_Bird

Very encouraging movement here. One whiff of Licence extension or rig signing and we are in for one hell of a ride

Liking the movement.

New management team since that update itsgambling ... market seem totally oblivious to that fact or ignoring it. Berwick calls the shots operationally now.

......We saw what happened in HEMO... Pharma can absolutely ignite on positve trial results.

with my first tranche. I remember being in the IPO back in 2015..... sounding below: " Placing at 37p(EIS Qualifying) - Valuing the company at �27m post money IPO date- 21st October Evgen are a clinical stage drug development company focused on oncology and neurology. � Their objective is to establish a dominant position in the development of pharmaceuticals based on sulforaphane in multiple indications. Sulforaphane is a naturally occurring molecule derived from brassica vegetables such as broccoli. � Sulforaphane has shown to reduce proliferation and induce programmed cell death in many cancers. It has shown to have neuro-protective effects in strokes, traumatic brain injury, multiple sclerosis, Alzheimers and Parkinson�s disease. There is also encouraging phase II data in prostate cancer and autism. � To date, despite considerable evidence supporting sulforaphane�s therapeutic properties, issues surrounding the drug�s stability, storage and delivery have hindered its development. Pure sulforaphane is a liquid that requires storage at -20oC, and therefore clinical and commercial development has, to date, been inhibited by the instability of the molecule. � The company�s core technology, Sulfradex, allows for the production of a synthetic and stable version of the compound, unlocking the medical and commercial potential of the drug. Lead compound is SFX-01. It can be formulated as a powder, capsule or tablet. � The company are raising �7m at IPO (originally �5m raise planned). This funding will advance SFX-01 through a Phase IIa trial in metastatic breast cancer with Cancer Research UK institute Manchester, a Phase II in subarachnoid haemorrhage (a type of stroke) with University Hospital Southampton, and allow them to complete preclinical trials in multiple sclerosis. The extra �2m raised will also allow another Phase II trial, likely to be in prostate cancer or autism. � Housebroker Northland has completed a discounted cash flow analysis indicating a fair value post money of �72m assuming a �5m raise, with considerable opportunity for further upside. Pre-money valuation at IPO is �20m. Considering �7m was raised at IPO we would expect an upgrade to DCF as the company will have enough funds to an extra Phase II trial. � We believe this valuation looks good value considering the lead compound is Phase II ready and IPO funding will traverse value inflexion points from at least 2 clinical studies. It also has a lower risk profile than many small pharmas due to the wealth of scientific literature that already exists on sulforaphane." Now MC is �12.5m and sp is 14p, yet it is now fully funded for the phase two trials and all importanly the cancer cell readout is due in Q1, matter of weeks! We saw what happened in HEMO... Pharma can absolutely ignite on posit

on BFS my personal target here.

Fair enough Stork all about risk v reward. You wait for clarity on them you'll be paying fair whack higher IMO albeit taking on lower risk. I have 50% holding atm and will double up on the confirmation news. I just cant ignore the upside here and back Berwick to deliver. 15% lower at the moment with new CEO in place. OP $65. SP all time lows near enough.

see this really breaking out. Fully funded and drilling in the summer. 250-300p move imo

finance package likely to come hand in had with BFS seeing at is China Coal paying/carrying out the BFS and its them who will fund JK

Upside case here is x 10 bags from here. News pending: BFS for JK Funding JK Off takes for JK Buyout of Debiensko by JSW and/or Cooporation agreement Any one of these I see a big big rerate here. Exciting times

For a non holder you are smothering this BB like there is no tomorrow. Again its obvious to see why. If you believe the company will spud a well here in H1 assuming a �2m placing AAOG offers the largest upside vs current Mcarket cap out of any other O&G company spudding this year bar none and thats a fact. Its a bet on management, new management to deliver on the company promises. Licence or not. 2 years 5 months on AAOGs licence is ample time to sort a renewal, I can pick out a fair few oil and gas stocks on AIM with only a year or so left on their licences and noone is making a song and dance out of it. AAOG doesnt have to either. Ill highlight, this is about New management. SP here at the moment is 15% lower with James Berwick calling the shots than it was with just Sefton. "The market is ususally right" The contraty to this opinion is precisely how I make my money on AIM. The market is an incredibly dumb animal over the short term (2-6 month timescale). Its a wiser beast long term and thats where the opportunity arises. If your argument stacks up then why was UKOG valued at over �250m? its about spotting the move before it happens or early and most importantly gearing the risk/reward in your favour.

Should read: AAOG is now 15% cheaper to buy now with James berwick as CEO than it was when Sefton was running the show..... never been cheaper.

Than when the company signed a new CEO - James Berwick. James Berwick credentials better than most on AIM. Clearly I see something the market doesnt here. This is more of a buy now then has been for many many months.

Would expect an RNS here either way by month end, thatll be 2 full months and a bit extra.

max buy...

$4.1m cash end of Sept after having paid $700k up front for long lead drilling items ($300k of that needs reimbursing) Their share of the remaining drill cost is $2m. People also forget Tilapia is producing at 42boped at the moment. This wasn�t factored in to H1 results due to down time and also AAOG only doing secondary competition after period end. Admin overheads/expenses are around �1m pa. Listing costs �400k pa. 42boepd is piddly but still $500k per year net to AAOG at current oil price. Upside prize here is �760m NPV from memory on success case. Binary play this until rig and spud date but I personally like the odds down here �6.8m mcap. All about risk/reward Even if a �2m raise is required pre spud (likely) there is still huge upside which is why im quite comfortable. The licence has 2 years and 5 months left on it and there wont risk losing rig A if that is secured before renewal. Hope this helps

Cracking RNS! "project economics are likely to be significantly enhanced compared to the 2016 Pre-Feasibility Study"

about to fall?

Nice find! Wowzers. Upside case here boggles my mind.

looking like its about to have an attack on 45p-50p zone this month. News on Total farm expected. This Guyana licence perhaps the number one O&G licence across the whole of AIM atm. Absolute gold dust. Right smack bang next to Exxons billion barrel discoveries, up dip.